Gonvers J J, Aenishänslin W, Backwinkel K, Bretholz A, Egger G, Feyerabend H, Fumagalli I, Güller R, Hammer B, Mattle W P
Division of Gastroenterology CHUV-PMU, University of Lausanne.
Hepatogastroenterology. 1987 Oct;34(5):233-5.
Seventy-nine patients with endoscopically confirmed gastric ulcers received either ranitidine (37 patients) or misoprostol (42 patients) in a randomized double-blind manner. Fifty-six percent of the patients treated with ranitidine, and 38% of those treated with misoprostol presented with endoscopically healed ulcers after four weeks of treatment. After eight weeks complete healing had occurred in 86% of the patients receiving ranitidine, and 74% of those on misoprostol. These differences were not statistically significant. In smokers, ranitidine was superior to misoprostol, leading to a higher healing rate at four weeks (73% versus 20%). Thus there was no evidence that in patients with gastric ulcer misoprostol overcomes the negative effect of cigarette smoking.